ChengDa Pharmaceuticals Co., Ltd. (SHE:301201)

ChengDa Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	445.5	178.46	1,364	604.43	18.49	47.02
Trading Asset Securities	645.13	957.65	-	776.89	-	-
Cash & Short-Term Investments	1,091	1,136	1,364	1,381	18.49	47.02
Cash Growth	-16.33%	-16.70%	-1.26%	7369.47%	-60.67%	-28.34%
Accounts Receivable	130.86	97.75	126.68	111.13	93.08	63.8
Other Receivables	0.63	0.17	0.19	0.01	0.49	0.01
Receivables	131.49	97.92	126.87	111.14	93.56	63.9
Inventory	127.03	135.27	130.47	156.43	104.18	57.97
Prepaid Expenses	-	-	-	-	4.02	-
Other Current Assets	60	45.86	21.59	30.88	5.67	4.64
Total Current Assets	1,409	1,415	1,643	1,680	225.93	173.52
Property, Plant & Equipment	827.53	872.25	646.21	518.45	402.21	304.03
Long-Term Investments	7.41	7.41	30	30	-	-
Other Intangible Assets	36.13	36.51	33.85	34.58	39.83	41.05
Long-Term Deferred Tax Assets	8.38	8.06	4.29	4.23	2.79	2.35
Long-Term Deferred Charges	40.65	44.12	43.5	12.93	6.47	7.17
Other Long-Term Assets	60.2	52.94	54.6	41.95	6	6.09
Total Assets	2,389	2,436	2,455	2,322	683.23	534.21
Accounts Payable	138.35	189.23	139.89	77.82	57.83	31.06
Accrued Expenses	7.13	11.96	9.71	10.76	6.84	4.51
Short-Term Debt	-	-	-	-	54.06	10.01
Current Portion of Long-Term Debt	-	-	-	-	15	-
Current Income Taxes Payable	0.46	0.1	5.63	0.04	4.87	8.03
Current Unearned Revenue	2.83	2.79	11.87	6.18	7.82	1.92
Other Current Liabilities	4.44	2.69	4.43	4.74	1.37	14.3
Total Current Liabilities	153.22	206.76	171.53	99.54	147.78	69.84
Long-Term Debt	88.2	80.12	-	-	-	-
Long-Term Unearned Revenue	2.31	2.51	3.43	4.47	5.52	5.46
Long-Term Deferred Tax Liabilities	1.36	1.38	1.44	1.8	-	-
Total Liabilities	245.09	290.77	176.4	105.81	153.3	75.3
Common Stock	154.71	154.71	154.71	96.7	72.52	72.52
Additional Paid-In Capital	1,694	1,694	1,693	1,751	152.57	151.82
Retained Earnings	369.28	370.68	429.09	367.12	304.15	233.72
Treasury Stock	-57.07	-57.07	-	-	-	-
Comprehensive Income & Other	-19.2	-19.2	-	-	-	-
Total Common Equity	2,142	2,143	2,277	2,214	529.24	458.06
Minority Interest	2.71	2.64	1.8	1.68	0.68	0.85
Shareholders' Equity	2,144	2,146	2,279	2,216	529.93	458.91
Total Liabilities & Equity	2,389	2,436	2,455	2,322	683.23	534.21
Total Debt	88.2	80.12	-	-	69.06	10.01
Net Cash (Debt)	1,002	1,056	1,364	1,381	-50.56	37.01
Net Cash Growth	-22.94%	-22.58%	-1.26%	-	-	-
Net Cash Per Share	6.61	6.95	8.82	9.12	-0.44	0.32
Filing Date Shares Outstanding	151.47	151.47	154.71	154.71	116.04	116.04
Total Common Shares Outstanding	151.47	151.47	154.71	154.71	116.04	116.04
Working Capital	1,256	1,208	1,471	1,580	78.15	103.68
Book Value Per Share	14.14	14.15	14.72	14.31	4.56	3.95
Tangible Book Value	2,106	2,107	2,243	2,180	489.41	417.01
Tangible Book Value Per Share	13.90	13.91	14.50	14.09	4.22	3.59
Buildings	-	325.77	256.48	227.07	184.8	129.63
Machinery	-	701.73	430.36	328.86	313.05	248.56
Construction In Progress	-	101.46	179.17	153.53	70.7	66.63

Source: S&P Global Market Intelligence. Standard template. Financial Sources.